



Rezūm™


Water Vapor Therapy

Transform the BPH treatment experience for your patients with a durable, minimally invasive, office-based alternative to medical management

- First-line therapy option¹
- Low retreatment rate²
- Preserves sexual function³
- Doesn't require a permanent implant
- Able to treat prostates with hyperplasia of the lateral lobes, central zone and/or median lobe
- Included in 2018 AUA guidelines, dedicated CPT® code⁴

How does the Rezūm System work?

The Rezūm System is a transurethral thermal therapy that uses sterile water vapor (steam) to treat BPH by delivering targeted, controlled doses of thermal energy directly to the prostate gland, targeting and reducing the obstructive tissue that causes BPH.








Study results show that Rezūm™ Water Vapor Therapy demonstrates durability and significant, sustained BPH symptom relief through 4 years

Rezūm Water Vapor Thermal Therapy for Lower Urinary Tract Symptoms Associated with Benign Prostatic Hyperplasia: 4-Year Results from Randomized Controlled Study

In Press: *Urology*, January 2019 | Authors: McVary KT, Rogers T, Roehrborn CG

The latest published analysis offers evidence that Rezūm Water Vapor Therapy demonstrates significant, sustained improvement of lower urinary tract symptoms (LUTS) and QOL for patients treated for benign prostatic hyperplasia (BPH) through 4 years post-procedure. Improvements as measured by IPSS, QOL, Qmax and BPHII show durability with consistent improvement from initial reporting at 3 months.

4-Year Study Data by the Numbers⁵

 135 Subjects 15 Sites	Durable	Sustained Results	
	Surgical Retreatment Rate 4.4%	International Prostate Symptom Score (IPSS)  10.1 pts (46.7%)	Quality of Life Impact (QOL)  2.0 pts (42.9%)
		Maximum Flow Rate (Qmax)  4.2 mL/sec (49.5%)	BPH Impact Index (BPHII)  3.5 pts (52.2%)

In addition to symptom and QOL improvements, surgical retreatment was low, with surgical intervention performed on just 4.4% of subjects through 4 years. Study results show a positive safety profile with preservation of sexual function, and no late-occurring related adverse events or de novo erectile dysfunction reported at 4 years.

To learn more about Rezūm Water Vapor Therapy or our portfolio of BPH treatment options, contact your Boston Scientific representative or visit bostonscientific.com/bph

1. Roehrborn CG, Gange SN, Gittelman MC, et al. Convective water vapor energy (WAVE) ablation therapy: durable two-year results and prospective blinded crossover study for treatment of lower urinary tract symptoms due to benign prostatic hyperplasia. *J Urol*. 2017 Jun;197(6):1507-1516
2. McVary KT, Roehrborn CG. Three-year outcomes of the prospective, randomized controlled Rezūm system study: convective radiofrequency thermal therapy for treatment of lower urinary tract symptoms due to benign prostatic hyperplasia. *Urology*. 2018 Jan;111:1-9.
3. McVary KT, Gange SN, Gittelman MC, et al. Minimally invasive prostate convective water vapor energy ablation: a multicenter, randomized, controlled study for the treatment of lower urinary tract symptoms secondary to benign prostatic hyperplasia. *J Urol*. 2016 May;195(5):1529-1538.
4. Foster HE, Barry MJ, DahmP, et al. Surgical management of lower urinary tract symptoms attributed to benign prostatic hyperplasia: AUA Guideline. *J Urol*. 2018 Sep;200(3):612-9.
5. McVary KT, Rogers T, Roehrborn CG. Rezūm water vapor thermal therapy for lower urinary tract symptoms associated with benign prostatic hyperplasia: 4-year results from randomized controlled study. *Urology Gold Journal*. 2019 Jan 23. [Epub ahead of print]

Results from clinical studies are not predictive of results in other studies. Results in other studies may vary. Caution: U.S. Federal law restricts this device to sale by or on the order of a physician.

Current Procedural Terminology (CPT) Copyright 2018 American Medical Association. All rights reserved. CPT is a registered trademark of the American Medical Association. Applicable FARS/DFARS Restrictions apply to government use. Fee schedules, relative value units, conversion factors, and/or related components are not assigned by the AMA, are not part of CPT, and the AMA is not recommending their use. The AMA does not directly or indirectly practice medicine or dispense medical services. The AMA assumes no liability for data contained or not contained herein.

All images are the property of Boston Scientific. All trademarks are the property of their respective owners.



Boston Scientific Corporation
 300 Boston Scientific Way
 Marlborough, MA 01752
www.bostonscientific.com

Ordering Information
1.888.272.1001

© 2019 Boston Scientific Corporation or its affiliates. All rights reserved.

URO-603903-AA JAN 2019